SOURCE: LipidViro Tech, Inc.

May 31, 2007 08:00 ET

LipidViro Tech Inc. to Present at IN3 Medical Device Summit

Proprietary Anti-Inflammatory Treatment for Acute Ischemic Stroke and Chronic Heart Failure

SALT LAKE CITY, UT--(Marketwire - May 31, 2007) - LipidViro Tech, Inc. (OTCBB: LPVT), a medical device company developing a new device-based, multi-therapeutic platform -- d-OSAB -- targeting acute ischemic stroke and chronic heart failure, announced that J. S. Latino, co-founder and Head of Research, and Linda Sharkus, Ph.D., Director, will attend Medtech Insight's "Investment In Innovation Medical Device Summit: A Preview of Early-Stage Medical Technology Companies" being held June 3-5, 2007, at the Grand Hyatt Hotel in San Francisco.

Mr. Latino's presentation is scheduled for 2:30 p.m. PDT on Monday, June 4, and will include an overview of the Company's proprietary technology, competitive advantages, plan to commence a 100-patient Phase IIa ischemic stroke study, and commercialization strategy.

About LipidViro Tech, Inc.

LipidViro Tech is a development-stage medical device company engaged in research and commercial development of its device-based, multi-therapeutic platform -- d-OSAB -- to treat ischemic brain stroke and chronic heart failure, diseases with few viable treatment options at present and markets exceeding $20 billion annually in the U.S. and EU. Stroke is the second leading cause of death worldwide, responsible for 4.4 million deaths each year. Annually, more than 1.5 million people in the U.S. and EU become victims of ischemic stroke. The single approved therapeutic for ischemic brain stroke patients is Tissue Plasminogen Activator (tPA), but patients are eligible for tPA only during a three-hour window from time of stroke; tPA use after three hours causes bleeding in the brain which may prove fatal. Consequently, only 6% of U.S. stroke patients and less than 1% of EU stroke patients utilize tPA. Anecdotal data suggests d-OSAB may be an effective stroke therapeutic for the majority of those untreated patients. During 2007, the Company is scheduled to commence a 100-patient Phase IIa study -- using d-OSAB to treat patients who have suffered an ischemic brain stroke -- to confirm these clinical findings.

Forward-looking Statements

This release contains forward-looking statements concerning plans, objectives, goals, strategies, future events or performance, which are not statements of historical fact. The forward-looking statements contained in this release reflect Management's current beliefs and expectations. Actual results or performance may differ materially from what is expressed in the forward-looking statements. Readers are referred to the documents filed by the Company with the SEC, specifically reports on Form 10-K and Form 10-Q including risk factors that could cause actual results to differ from forward-looking statements. These reports are available at www.sec.gov.

Contact Information

  • Contact:
    Allen & Caron
    Dan Matsui
    949-474-4300

    LipidViro Tech, Inc.
    Linda Sharkus, PhD
    732-280-8425
    lcs@lipidviro.com